ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Evaluation of serum Cytokeratin 5 and p63 as non-invasive biomarkers for the diagnosis and staging of cervical cancer: a case-control study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer continues to be a major worldwide health concern. Diagnostic methods are limited, and therefore, more specific, non-invasive serum biomarkers are required for greater efficacy in detecting and monitoring the disease.
objectiveThis research aims to investigate the diagnostic and prognostic utility of serum Cytokeratin 5 (CK5) and p63 as biomarkers for cervical cancer. MATERIAL AND
methodsA case-control study was conducted with 50 women with newly diagnosed, histologically confirmed cervical cancer and 50 age-matched healthy controls. Serum levels of CK5 and p63 were quantified using enzyme-linked immunosorbent assay (ELISA).
resultsSerum levels of both CK5 (286 ± 94 vs. 77.5 ± 28.2 ng/L, p < 0.001) and p63 (35.1 ± 10.6 vs. 7.5 ± 3.2 ng/mL, p < 0.001) were significantly elevated in cervical cancer patients compared to controls. ROC analysis revealed excellent diagnostic accuracy, with an area under the curve (AUC) of 0.96 for CK5 and 0.97 for p63 both biomarkers being statistically significantly more in advanced-stage than in early-stage of the disease on p = 0.002 and p < 0.0001, respectively, and independent predictors of advanced disease in multivariate analysis.
conclusionSerum CK5 and p63 had an excellent diagnostic efficiency for cervical cancer and correlated with disease progression, positioning them as promising non-invasive biomarkers for diagnosis and staging.
Indexed as
Identifiers
41722012What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.